Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ABOS

Acumen Pharmaceuticals Inc

May 07 • 12:35PM ET

3.42

Dollar change -0.14
Percentage change -3.93	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFAS IBRN

Index	-	P/E	-	EPS (ttm)	-1.08	Insider Own	27.33%	Shs Outstand	57.91M	Perf Week	6.21%
Market Cap	205.47M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	-0.21%	Shs Float	43.66M	Perf Month	-12.08%
Income	-52.37M	PEG	-	EPS next Q	-0.26	Inst Own	55.77%	Short Float	2.40%	Perf Quarter	7.21%
Sales	0.00M	P/S	-	EPS this Y	-8.51%	Inst Trans	4.20%	Short Ratio	3.20	Perf Half Y	56.16%
Book/sh	4.61	P/B	0.74	EPS next Y	-19.42%	ROA	-20.67%	Short Interest	1.05M	Perf Year	-35.35%
Cash/sh	4.05	P/C	0.84	EPS next 5Y	22.89%	ROE	-22.98%	52W Range	1.81 - 11.31	Perf YTD	-10.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-54.03%	ROI	-17.62%	52W High	-69.76%	Beta	0.21
Dividend TTM	-	Quick Ratio	19.01	Sales past 5Y	-28.84%	Gross Margin	-	52W Low	88.94%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	19.01	EPS Y/Y TTM	-2.55%	Oper. Margin	0.00%	RSI (14)	46.73	Volatility	5.84% 5.63%
Employees	52	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	13.50
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	9.53%	Payout	-	Rel Volume	0.27	Prev Close	3.56
Sales Surprise	-100.00%	EPS Surprise	-2.30%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	328.15K	Price	3.42
SMA20	0.59%	SMA50	-10.97%	SMA200	-16.09%	Trades		Volume	43,972	Change	-3.93%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-23	Initiated	Deutsche Bank	Buy	$8
Jul-20-23	Resumed	BofA Securities	Buy	$9 → $14
May-18-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jul-15-22	Initiated	BTIG Research	Buy	$15
Jun-30-22	Initiated	H.C. Wainwright	Buy	$15
Jan-21-22	Upgrade	BofA Securities	Neutral → Buy	$16 → $14
Jul-26-21	Initiated	UBS	Buy	$27
Jul-26-21	Initiated	Stifel	Buy	$27
Jul-26-21	Initiated	Credit Suisse	Outperform	$26
Jul-26-21	Initiated	BofA Securities	Neutral	$20

Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-16-24 08:00AM	Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-08-24 05:38PM	13 Best Penny Stocks to Buy According to Billionaire Ken Griffin (Insider Monkey)
Apr-04-24 02:12PM	Acumen Pharmaceuticals Collaborates with Lonza For Alzheimers Treatment (Exec Edge)
08:00AM	Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease (GlobeNewswire)
08:38AM	Loading…
Apr-03-24 08:38AM	Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick (Zacks)
Mar-28-24 12:00PM	Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-27-24 09:46AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.33%
Mar-26-24 09:20PM	Q4 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -11.76%
11:52AM	ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights (GlobeNewswire)
Mar-21-24 10:41AM	Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-19-24 04:00PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 (GlobeNewswire)
Mar-18-24 10:31AM	15 Best Anti-Aging Foods for Youthful Skin (Insider Monkey)
04:00PM	Loading…
Mar-12-24 04:00PM	Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days (GlobeNewswire)
Mar-08-24 08:50AM	Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting (GlobeNewswire)
Feb-29-24 09:40AM	Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-21-24 08:00AM	Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting (GlobeNewswire)
Feb-01-24 07:00AM	Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer (GlobeNewswire)
Jan-30-24 02:14PM	Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot (InvestorPlace)
Jan-24-24 01:58PM	3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom (InvestorPlace)
Jan-04-24 04:15PM	Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-14-23 08:53AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 11:08PM	Q3 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +6.84%
10:54AM	Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update (GuruFocus.com)
09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
07:00AM	Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures (GlobeNewswire)
07:00AM	Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-07-23 04:01PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire)
11:22AM	Loading…
11:22AM	Q3 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 04:01PM	Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023 (GlobeNewswire) -5.02%
07:30AM	Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE Technology (GlobeNewswire)
Nov-02-23 04:00PM	Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference (GlobeNewswire)
Oct-27-23 09:25AM	Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease (GlobeNewswire) -24.84%
Oct-04-23 08:00AM	Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) (GlobeNewswire)
Sep-19-23 04:00PM	Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:00PM	Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 10:21PM	Q2 2023 Acumen Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-01-23 04:00PM	Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023 (GlobeNewswire)
Jul-25-23 01:47PM	Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-18-23 10:31PM	Acumen Announces Pricing of Upsized $130 Million Public Offering (GlobeNewswire) -17.70%
11:32AM	Why Shares of Acumen Pharmaceuticals Are Down Tuesday (Motley Fool)
Jul-17-23 04:53PM	Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +54.78%
07:00AM	Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimers Disease (GlobeNewswire)
Jul-16-23 03:00AM	Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimers Disease at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
02:00AM	Acumen's Alzheimer's drug passes initial safety test (Reuters)
Jul-03-23 05:13PM	12 Best NASDAQ Penny Stocks to Buy (Insider Monkey)
Jun-28-23 06:30AM	Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla (GlobeNewswire)
Jun-13-23 07:00AM	Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimers Disease During Featured Research Session at the Alzheimers Association International Conference (AAIC®) 2023 (GlobeNewswire) +13.49%
May-16-23 12:41PM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript (Insider Monkey) -9.52%
May-09-23 07:00AM	Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +18.14%
May-04-23 04:01PM	Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference (GlobeNewswire)
May-02-23 04:01PM	Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023 (GlobeNewswire) -6.09%
Apr-09-23 08:57AM	Institutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the company (Simply Wall St.)
Mar-29-23 07:30AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-28-23 08:00AM	Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimers Disease (GlobeNewswire)
Mar-27-23 07:00AM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights (GlobeNewswire) +7.40%
Mar-22-23 04:01PM	Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days (GlobeNewswire) +5.15%
Mar-20-23 04:01PM	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023 (GlobeNewswire)
Mar-08-23 04:01PM	Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum (GlobeNewswire)
Feb-15-23 12:07PM	Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-13-23 08:00AM	Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic A Oligomers in Patients with Early Alzheimers Disease (GlobeNewswire)
Jan-06-23 09:40AM	Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year? (Zacks) -8.55%
Jan-04-23 08:00AM	Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors (GlobeNewswire)
Dec-29-22 06:02AM	Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript (Insider Monkey) +11.64%
Nov-14-22 04:01PM	Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) -9.71%
Nov-09-22 04:01PM	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.45%
Nov-07-22 04:01PM	Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022 (GlobeNewswire)
Nov-01-22 08:00AM	Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimers Disease (GlobeNewswire)
Oct-24-22 08:00AM	Acumens ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease (GlobeNewswire)
Sep-08-22 12:44PM	We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-15-22 11:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript (Motley Fool)
04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights (GlobeNewswire)
Aug-08-22 04:15PM	Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-01-22 10:30AM	Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimers disease (GlobeNewswire) -8.09%
Jul-26-22 04:15PM	Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Jun-08-22 08:00AM	Hopeful week for insiders who might be regretting buying US$5.7m of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) stock earlier this year (Simply Wall St.)
May-16-22 10:00PM	Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript (Motley Fool)
04:05PM	Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights (GlobeNewswire)
May-11-22 05:08PM	Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire) -14.21%
Apr-27-22 08:00AM	Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals New Approach to Treating Alzheimer's Disease (GlobeNewswire)
Apr-02-22 12:00AM	Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript (Motley Fool)
Apr-01-22 05:01PM	We're Hopeful That Acumen Pharmaceuticals (NASDAQ:ABOS) Will Use Its Cash Wisely (Simply Wall St.)
Mar-28-22 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights (GlobeNewswire) -9.34%
Mar-16-22 04:15PM	Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 (GlobeNewswire) +11.72%
Dec-30-21 04:16AM	Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last year (Simply Wall St.)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-15-21 08:00AM	Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights (GlobeNewswire) -8.49%
Nov-08-21 08:00AM	Acumen Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-21 08:00AM	Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Oct-07-21 08:00AM	Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic A Oligomers for the Treatment of Early Alzheimers Disease (GlobeNewswire)
Oct-01-21 06:05AM	Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-16-21 04:05PM	Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights (GlobeNewswire)
Jul-23-21 07:13PM	Landmark Infrastructure, CVRx See Activist Action (Barrons.com)
Jul-01-21 05:02PM	Krispy Kreme IPO Gains Nearly 24% in Busy Week for Deals (Barrons.com)
11:14AM	Acumen Pharmaceuticals shares soar 25% in trading debut (MarketWatch)
Jun-30-21 10:44PM	Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OConnell Daniel Joseph	President and CEO	Jan 19 '24	Sale	3.47	15,200	52,753	502,485	Jan 19 07:07 PM
Meisner Derek M	Chief Legal Officer & Corp Sec	Jan 19 '24	Sale	3.48	8,933	31,048	108,867	Jan 19 07:06 PM
Zuga Matt	CFO & Chief Business Officer	Jan 18 '24	Sale	3.71	4,242	15,717	211,445	Jan 19 07:05 PM
Siemers Eric	Chief Medical Officer	Jan 18 '24	Sale	3.71	3,124	11,604	117,576	Jan 19 07:05 PM
Barton Russell	Chief Operating Officer	Jan 18 '24	Sale	3.73	2,833	10,555	96,867	Jan 19 07:04 PM
Ives Jeffrey L.	Director	Aug 17 '23	Option Exercise	0.75	41,949	31,519	39,149	Aug 18 06:31 PM
Ives Jeffrey L.	Director	Aug 17 '23	Sale	6.49	41,949	272,334	0	Aug 18 06:31 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 21 '23	Buy	7.75	5,161,290	39,999,998	13,043,179	Jul 25 04:30 PM

Open in Screener

XFOR

X4 Pharmaceuticals Inc

May 07 • 12:36PM ET

1.07

Dollar change -0.13
Percentage change -11.25	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

XFOR X4 Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IWN VTWO IWO IWC VTWG IWV VTWV

Index	RUT	P/E	-	EPS (ttm)	-0.60	Insider Own	27.30%	Shs Outstand	167.43M	Perf Week	-4.91%
Market Cap	178.86M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-0.40%	Shs Float	122.08M	Perf Month	-17.44%
Income	-101.17M	PEG	-	EPS next Q	-0.18	Inst Own	35.45%	Short Float	10.05%	Perf Quarter	16.39%
Sales	0.00M	P/S	-	EPS this Y	15.54%	Inst Trans	67.22%	Short Ratio	3.88	Perf Half Y	12.62%
Book/sh	0.31	P/B	3.49	EPS next Y	5.34%	ROA	-66.81%	Short Interest	12.26M	Perf Year	-37.35%
Cash/sh	0.68	P/C	1.56	EPS next 5Y	-	ROE	-161.67%	52W Range	0.57 - 2.58	Perf YTD	27.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	73.95%	ROI	-93.43%	52W High	-58.64%	Beta	0.43
Dividend TTM	-	Quick Ratio	5.34	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	86.09%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	5.34	EPS Y/Y TTM	67.74%	Oper. Margin	0.00%	RSI (14)	43.08	Volatility	8.43% 12.64%
Employees	93	Debt/Eq	1.14	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	4.12
Option/Short	Yes / Yes	LT Debt/Eq	1.12	EPS Q/Q	66.69%	Payout	-	Rel Volume	1.91	Prev Close	1.20
Sales Surprise	-	EPS Surprise	-68.50%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	3.16M	Price	1.07
SMA20	-12.02%	SMA50	-8.07%	SMA200	2.66%	Trades		Volume	3,037,233	Change	-11.25%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral	$3 → $1
Aug-30-23	Resumed	B. Riley Securities	Buy	$3
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight	$3
Dec-12-22	Initiated	Piper Sandler	Overweight	$3
Dec-23-19	Initiated	Oppenheimer	Outperform	$20
Dec-18-19	Initiated	ROTH Capital	Buy	$20
Dec-09-19	Upgrade	Citigroup	Neutral → Buy	$16 → $20
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy	$27
Jun-05-19	Initiated	Cowen	Outperform

Today 10:54AM	XFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -11.25%
06:07AM	X4 Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:01AM	X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-24 09:32AM	HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating (MT Newswires)
08:00AM	Loading…
08:00AM	X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 (GlobeNewswire)
Apr-29-24 11:19AM	X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome (MT Newswires) -6.44%
06:47AM	UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease (Reuters)
06:30AM	X4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome (GlobeNewswire)
Apr-02-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-24 08:00AM	X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-22-24 12:47PM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.45%
Mar-21-24 10:09PM	Q4 2023 X4 Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +28.43%
10:53AM	XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results (GuruFocus.com)
06:01AM	Loading…
06:01AM	X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-12-24 08:00AM	X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024 (GlobeNewswire) -5.23%
Mar-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.51%
Dec-09-23 12:00PM	X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 (GlobeNewswire)
Dec-04-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
Nov-10-23 03:46PM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.03%
08:00AM	X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
01:48AM	Q3 2023 X4 Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 09:29AM	X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +6.68%
06:01AM	X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-02-23 08:00AM	X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023 (GlobeNewswire) +6.47%
Nov-01-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.13%
Oct-31-23 08:00AM	X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome (GlobeNewswire) +9.28%
Oct-18-23 08:00AM	X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors (GlobeNewswire) -5.24%
04:05PM	Loading…
Oct-02-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.25%
Sep-19-23 08:00AM	X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 08:00AM	X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome (GlobeNewswire)
Sep-01-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-23 10:53AM	XFOR: NDA for Mavorixafor in WHIM Syndrome in Early 2H23 (Zacks)
Aug-10-23 06:38AM	X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -35.98%
06:05AM	X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program (GlobeNewswire)
Aug-08-23 04:05PM	X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer (GlobeNewswire)
Aug-03-23 08:00AM	X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital (GlobeNewswire)
Aug-02-23 08:01AM	X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023 (GlobeNewswire)
Jun-30-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 06:26AM	XFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM (Zacks Small Cap Research)
Jun-13-23 08:00AM	X4 Pharmaceuticals Expected to Join Russell 3000® Index (GlobeNewswire) +9.69%
Jun-02-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-23 04:01PM	X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome (GlobeNewswire) +15.79%
08:30AM	X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market (GlobeNewswire)
May-15-23 04:44AM	Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review (Investing.com)
May-04-23 06:12AM	X4 Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
06:05AM	X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-23 12:32PM	X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32% (Simply Wall St.) +11.11%
08:01AM	X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023 (GlobeNewswire)
Apr-12-23 08:00AM	X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire) +19.99%
Apr-04-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.29%
Mar-24-23 07:36AM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-21-23 06:05AM	X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-23 08:01AM	X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023 (GlobeNewswire) +9.47%
Mar-02-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-31-23 12:00PM	What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock (Zacks) +5.67%
Dec-12-22 08:30AM	X4 Pharmaceuticals Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia (GlobeNewswire)
Dec-07-22 08:43AM	X4 Pharmaceuticals Prices $65.0 Million Public Offering (GlobeNewswire) -14.17%
Dec-06-22 06:26PM	X4 Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire) -6.98%
Nov-30-22 08:05AM	X4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency Candidate (Benzinga) -18.92%
Nov-29-22 04:01PM	X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome (GlobeNewswire) +5.11%
Nov-17-22 09:51AM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) most popular amongst individual investors who own 40% of the shares, institutions hold 34% (Simply Wall St.)
Nov-08-22 08:00AM	X4 Pharmaceuticals to Present at Stifel Healthcare Conference (GlobeNewswire)
Nov-04-22 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-22 06:05AM	X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-22 08:00AM	X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer (GlobeNewswire)
Oct-20-22 08:00AM	X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022 (GlobeNewswire)
Sep-27-22 10:49AM	X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia (Benzinga) +40.18%
07:50AM	X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafors Broad Potential in Chronic Neutropenia (CN) (GlobeNewswire)
Aug-31-22 08:30AM	X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia (GlobeNewswire) +7.62%
Aug-18-22 12:00PM	All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy (Zacks)
Aug-08-22 04:05PM	X4 Pharmaceuticals to Present at Canaccord Genuitys 42nd Annual Growth Conference (GlobeNewswire)
Aug-04-22 07:05AM	X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-22 04:05PM	X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022 (GlobeNewswire)
Jul-21-22 02:46PM	X4 Pharmaceuticals lays off 20% of staff, stops work on cancer drugs (American City Business Journals) +9.65%
07:58AM	X4 Pharma To Stop Further Work On Oncology Programs, Looks For Partner(s) (Benzinga)
Jul-20-22 04:10PM	X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones (GlobeNewswire)
Jul-01-22 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.77%
Jun-30-22 07:52PM	X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months (GlobeNewswire) +9.66%
Jun-23-22 07:00AM	Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer (GlobeNewswire)
May-16-22 06:05AM	X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor (GlobeNewswire)
May-12-22 07:15AM	X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:05AM	X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 06:05AM	X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022 (GlobeNewswire)
May-02-22 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-08-22 01:05PM	X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Apr-04-22 08:05AM	X4 Pharmaceuticals to Present at April Investor Conferences (GlobeNewswire)
Apr-01-22 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
Mar-17-22 06:05AM	X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -10.61%
Mar-08-22 08:00AM	X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022 (GlobeNewswire)
Mar-03-22 08:00AM	X4 Pharmaceuticals to Present at March Investor Conferences (GlobeNewswire) +7.61%
Mar-01-22 10:15AM	Billionaire Steven Cohen Loads Up on These 2 Penny Stocks (TipRanks) +20.00%
08:00AM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-22 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.85%
Jan-19-22 08:00AM	X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference (GlobeNewswire)
Jan-05-22 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.75%
Dec-13-21 12:52PM	Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low? (Benzinga) -44.13%

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mostafa Adam S.	Chief Financial Officer	Mar 11 '24	Sale	0.88	52,500	46,347	0	Mar 11 05:19 PM
Ragan Paula	President and CEO	Mar 11 '24	Sale	0.88	49,678	43,856	765,068	Mar 11 05:20 PM
DiBiase Mary	Chief Operating Officer	Mar 11 '24	Sale	0.88	15,409	13,591	291,752	Mar 11 05:19 PM
Taveras Arthur	Chief Scientific Officer	Mar 11 '24	Sale	0.88	14,235	12,552	234,301	Mar 11 05:20 PM
Mostafa Adam S.	Chief Financial Officer	Feb 12 '24	Sale	1.01	27,721	27,973	52,500	Feb 12 05:03 PM
Ragan Paula	President and CEO	Feb 12 '24	Sale	1.01	21,695	21,892	814,746	Feb 12 05:05 PM
DiBiase Mary	Chief Operating Officer	Feb 12 '24	Sale	1.01	3,683	3,709	307,161	Feb 12 05:23 PM
Taveras Arthur	Chief Scientific Officer	Feb 12 '24	Sale	1.01	787	793	248,536	Feb 12 05:23 PM
Ragan Paula	President and CEO	Nov 03 '23	Sale	0.90	39,906	35,915	836,441	Nov 03 05:26 PM
Mostafa Adam S.	Chief Financial Officer	Nov 01 '23	Sale	0.73	230,645	168,371	80,221	Nov 03 04:42 PM
Ragan Paula	President and CEO	Nov 01 '23	Sale	0.73	199,531	145,658	876,347	Nov 03 05:26 PM
DiBiase Mary	Chief Operating Officer	Nov 01 '23	Sale	0.73	67,695	49,417	310,844	Nov 03 04:40 PM
Taveras Arthur	Chief Scientific Officer	Nov 01 '23	Sale	0.73	67,695	49,417	249,323	Nov 03 04:39 PM
Baldry Mark	Chief Commercial Officer	Nov 01 '23	Sale	0.73	10,257	7,488	24,690	Nov 03 04:39 PM
DiBiase Mary	Chief Operating Officer	Sep 08 '23	Sale	1.25	2,642	3,300	147,894	Sep 12 04:04 PM
WYZGA MICHAEL S	Director	Aug 18 '23	Buy	1.20	25,000	29,875	76,667	Aug 22 04:09 PM
Stewart Murray	Interim Chief Medical Officer	Aug 10 '23	Sale	1.06	130,056	137,859	146,504	Aug 11 07:26 PM
Mostafa Adam S.	Chief Financial Officer	Jun 30 '23	Sale	1.89	2,641	4,991	80,221	Jul 05 04:04 PM
DiBiase Mary	Chief Operating Officer	Jun 30 '23	Sale	1.89	464	877	150,536	Jul 05 04:05 PM
Ragan Paula	President and CEO	Jun 23 '23	Sale	1.92	6,724	12,910	543,797	Jun 26 04:11 PM
Mostafa Adam S.	Chief Financial Officer	Jun 23 '23	Sale	1.93	5,417	10,455	82,862	Jun 26 04:13 PM
DiBiase Mary	Chief Operating Officer	Jun 23 '23	Sale	1.93	857	1,654	151,000	Jun 26 04:15 PM
Ragan Paula	President and CEO	Jun 15 '23	Sale	2.23	6,724	14,995	550,521	Jun 16 04:15 PM
Mostafa Adam S.	Chief Financial Officer	Jun 15 '23	Sale	2.22	5,417	12,026	88,279	Jun 16 04:17 PM
DiBiase Mary	Chief Operating Officer	Jun 15 '23	Sale	2.23	857	1,911	151,857	Jun 16 04:24 PM
Ragan Paula	President and CEO	May 31 '23	Sale	1.95	6,292	12,269	557,245	May 31 05:05 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ABOS

Acumen Pharmaceuticals Inc

XFOR

X4 Pharmaceuticals Inc

Upgrade your FINVIZ experience